In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease

Keyphrases

• Parkinson's Disease 100%
• Mass Spectrometry 100%
• Leucine-rich Repeat Kinase 2 (LRRK2) 100%
• G2019S 100%
• Blood Biomarkers 100%
• Rab12 100%
• R1441C 16%
• Parkinson Patients 16%
• Peripheral Blood Mononuclear Cells 16%
• Clinical Trials 11%
• Phosphorylation State 11%
• Clinical Cohort 11%
• Phosphoproteomics 11%
• Endogenous Biomarkers 11%
• Spain 5%
• Phosphorylation 5%
• Phosphoprotein 5%
• Kinase Activity 5%
• Mitochondria 5%
• Proteomic Analysis 5%
• LAMP1 5%
• Activating mutation 5%
• Mutation Carriers 5%
• Immunoblotting 5%
• Disease Severity 5%
• Healthy Controls 5%
• Pharmacodynamics 5%
• Drug Efficacy 5%
• Protein Signature 5%
• Endolysosomal System 5%
• G2019S mutation 5%
• Machine Learning 5%
• Differentially Expressed Proteins 5%
• Patient Monitoring 5%
• Proteostasis 5%
• Disease Modification 5%
• Disease-modifying Therapy 5%
• MLi-2 5%
• RAB9A 5%
• Unified Parkinson's Disease Rating Scale (UPDRS) 5%
• Dynamic Progress 5%
• Patient Enrichment 5%
• PD Patients 5%
• Progression Biomarkers 5%
• Dynamic Readout 5%

Biochemistry, Genetics and Molecular Biology

• Phosphotransferase 100%
• Kinase 100%
• Mass Spectrometry 100%
• Leucine-Rich Repeat 100%
• LRRK2 58%
• Peripheral Blood Mononuclear Cell 25%
• Clinical Trial 16%
• Pharmacodynamics 8%
• Phosphoprotein 8%
• Mitochondrion 8%
• Proteome 8%
• Protein Homeostasis 8%
• Drug Efficacy 8%
• LAMP1 8%
• Immunoblotting 8%
• Proteomics 8%